Omnes Capital's exits

Sector 
SaaS / Cloud
Entry Date 
2010
Exit Date 
2011
Buyer 
Softbank
Business 
Venture Capital

Aldebaran Robotics

Production and marketing of humanoid robots

Founded in 2005 by Bruno Maisonnier with offices in France, China and the United States, Aldebaran Robotics develops, manufactures and markets interactive humanoid robots to serve humans. Today, NAO robots are used in over 30 countries around the world as research and educational platforms and by more than 300 universities and research organisations. Aldebaran Robotics has a team of over 100 employees–half of whom are engineers or hold PhDs–involved in the development, production and marketing of its robots, assembled from start to finish at its facilities in Paris.

Sector 
Web
Entry Date 
2010
Exit Date 
2011
Buyer 
Online Commerce Partners
Business 
Venture Capital

Oclio

Specialised in children’s safety and comfort equipment

Founded in 2003 and attracting over 350,000 visitors per month, Oclio, France’s leading online retailer of baby products, offers a full range of child care products for the well-being, comfort and safety of children aged from 0 to 4 years. Aside from large and small child care, Oclio offers a wide range of food, hygiene products, baby toys, clothing, furniture and decorations, and more broadly, natural and organic products. The website, which also has a presence in Italy and Spain, is geared to new parents and sells 6,500 products from 170 major brands in the sector.

Sector 
Hardware
Entry Date 
2003
Exit Date 
2011
Buyer 
Parrot
Business 
Venture Capital

DiBcom

Semiconductor company (integrated circuits for DTT)

Founded in June 2000, DiBcom is a French semiconductor company based on a fabless (no factory) model, that designs, manufactures and sells integrated circuits for receiving Digital Terrestrial television. DiBcom’s solution can be used in any type of terminal and ensures perfect reception of television channels in every situation–including on the move–irrespective of the standard used.

Sector 
SaaS / Cloud
Entry Date 
2005
Exit Date 
2011
Buyer 
Keynetis
Business 
Venture Capital

OpenTrust

From defensive security to digital trust

OpenTrust (formerly Idealx) develops software solutions to move on from defensive security to digital trust based on a “Trusted Ecosystem” in which each component (routers, networks, machines, servers, users, systems, applications, transactions, etc.) must trust the calling component and/or the one being called before it is executed. OpenTrust has more than one million users around the world who work for 70 large accounts and public administrations.

Sector 
Pharma
Entry Date 
2003
Exit Date 
2011
Buyer 
Amgen
Business 
Venture Capital

Biovex

Oncolytic vaccines used to treat cancer and infectious diseases

Biovex, which was founded in 1998, develops new vaccines used to treat cancer and chronic infectious diseases. The company has two proprietary platforms, namely OncoVEX and ImmunoVEX, based on genetic manipulation of the herpes simplex virus (HSV). Biovex recently completed a Phase II clinical trial for the treatment of melanoma with its OncoVEX GM-CSF product. The results of this trial showed that the product was capable of inducing a lasting response in a large proportion of the patients treated. The company is currently carrying out Phase III trials for this indication.
January 2011: Amgen completed the acquisition of BioVex for total consideration of up to $1 billion should it reach its milestones. 

 

Latest news
Sector 
SaaS / Cloud
Entry Date 
2009
Exit Date 
2010
Buyer 
Cloudmark
Business 
Venture Capital

Bizanga

Specialist in email management

Bizanga, a specialist in email management, sold its IMP (Intelligent Message Processor) email traffic management platform to US partner Cloudmark. Bizanga retains its storage business and has changed its name to Bizanga Store.

Latest news
Sector 
Pharma
Entry Date 
2006
Exit Date 
2009
Buyer 
Acquisition of a Pangenetics asset by Abbott
Business 
Venture Capital

PanGenetics

Development of innovative and unique humanised therapeutic antibodies.

Dutch company specialised in the clinical development of therapeutic antibodies. The company sold exclusive rights to its PG-110 antibody to Abbott for $190 million. Developed by PanGenetics, PG-110 is a humanised antibody targeting nerve growth factor (in phase I clinical trials). To date, the company has raised close to €51 million in the three funding rounds completed between 2005 and 2008. The deal is an endorsement of the company’s novel strategy predicated on the development of proprietary products and the licensing of new products, excluding R&D activities.

Sector 
Pharma
Entry Date 
2005
Exit Date 
2009
Buyer 
Sanofi Aventis
Business 
Venture Capital

Fovea Pharmaceuticals

Ocular franchise dedicated to discovering therapies for retinal conditions

Founded in 2005 to break new ground in the treatment of retinal conditions, Fovea Pharmaceuticals has built an R&D portfolio covering ocular conditions with unmet needs, and now forms Sanofi’s Ophthalmology division. Its core approach is to put patients at the heart of its strategy, thanks to its presence at the Institut de la Vision located on the Quinze-Vingts hospital campus. Its team consists almost exclusively of research scientists. 
The company was bought by Sanofi Aventis in 2009 in a deal worth up to €370 million.

 

Sector 
Pharma
Entry Date 
2004
Exit Date 
2009
Buyer 
Pharma Omnium International
Business 
Venture Capital

Mutabilis

Discovery of new therapeutic targets for the development of anti-infectives

Mutabilis is a biopharmaceutical company specialised in the discovery and development of anti-infectives. Mutabilis discovers and develops innovative anti-infectives, a novel class of drug addressing the current issues arising from resistance to antibiotics and targeting severe bacterial infections. Mutabilis’ new therapies target nosocomial infections in particular.

Sector 
Pharma
Entry Date 
2002
Exit Date 
2007
Buyer 
Biolipox merged with Orexo in November 2007
Business 
Venture Capital

Orexo

Specialty pharmaceutical company developing drugs from a proprietary delivery platform

Orexo is a Swedish pharmaceutical company specialised in the development of new patented drugs by combining well-known molecules with innovative technologies, chiefly for the treatment of inflammatory and respiratory conditions. Orexo possesses a large portfolio of products at an advanced development stage and which have already demonstrated therapeutic benefits. In 2007, Orexo merged with Biolipox, a pharmaceutical research & development company focused on inflammatory conditions, through an increase in capital valuing the company at an aggregate amount of $137 million. Orexo (ORX) is listed on the Stockholm Stock Exchange.
(N/a: Initial investment: Omnes Capital purchased a stake in Biolipox in December 2002)

Pages

NewsRoom
Press release
25 November 2019
Omnes welcomes on board two new Analysts
Omnes welcomes on board two new Analysts
Press release
20 November 2019
TISSIUM Closes €39M Series B Funding Round
TISSIUM Closes €39M Series B Funding Round
Publication
Table ronde à LP/GP : les clés de la relation. A lire dans le Magazine des Affaires avec la participation d'Omnes (avril 2019)
Press release
28 October 2019
Solvionic completes a €4 million funding round from Omnes and IRDI Soridec
Solvionic completes a €4 million funding round from Omnes and IRDI Soridec
Press release
08 October 2019
Omnes invests in Biosyl as part of a sponsorless deal
Omnes invests in Biosyl as part of a sponsorless deal
Press release
01 October 2019
Glennmont purchases 211MW unsubsidised Finnish wind project from Ilmatar Energy
Glennmont purchases 211MW unsubsidised Finnish wind project from Ilmatar Energy

Pages